Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
UnitedHealth Group Incorporated's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $338.3B | |
|---|---|---|
| Revenue (ttm) | 450.1B | |
| Net income (ttm) | 15.9B | |
| EPS (ttm) | $17.5 | |
| Shares out | 897.6M | |
| P/E (trailing) | 23.3x | |
| P/E (forward) | 16.7x | |
| Dividend | $9.28 (2.28%) | |
| Volume | 2,955,783 | |
| Beta | 0.61 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $287.60B | $324.16B | $371.62B | $400.28B | $447.57B | +11.7% |
| Gross profit | $69.65B | $79.62B | $90.96B | $89.40B | $82.92B | +4.5% |
| Operating income | $23.97B | $28.44B | $32.36B | $32.29B | $18.96B | -5.7% |
| Net income | $17.29B | $20.12B | $22.38B | $14.41B | $12.06B | -8.6% |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 | -7.5% |
| EBITDA | $27.07B | $31.84B | $36.33B | $28.08B | $23.06B | -3.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $42.58B | $47.78B | $54.63B | $53.01B | $59.59B | +8.8% |
Recent company headlines from major financial publishers.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.0% | $553 | $592 | $643 | $717 | $833 |
| 7.0% | $473 | $494 | $521 | $556 | $603 |
| 8.0% | $420 | $433 | $448 | $468 | $492 |
| 9.0% | $381 | $389 | $399 | $411 | $426 |
| 10.0% | $351 | $357 | $364 | $372 | $381 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
